A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

General Inclusion Criteria: * ≥ 18 years of age * Adequate organ function * Life expectancy ≥ 16 weeks * Women of childbearing potential must have a negative serum pregnancy test * High-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer * Received 1 or 2 prior regimens, including ≥ 1 prior platinum-based therapy and have platinum-sensitive disease * Relapsed/progressive disease (confirmed by radiologic assessment) * Willing and able to have a biopsy of tumor at screening and after 4 weeks of treatment. * Measurable disease (RECIST v1.1)- Cohort A1 only * ECOG performance status of 0 to 1 General Exclusion Criteria * Active second malignancy * Central nervous system brain metastases * Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis. * Active, known or suspected autoimmune disease (eg, autoimmune hepatitis). * Condition requiring systemic treatment with either corticosteroids * Prior treatment with a PARP inhibitor or immune checkpoint inhibitor. * Non-epithelial tumors (pure sarcomas) or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors. Mixed Mullerian tumors/carcinosarcomas are allowed.